SCHEMBL7220626

SCHEMBL7220626

O=C(O)CNCCOCC(=O)O

nearest known ligand 0.39

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 1/20 0.39
CYP2C19 P33261 1/20 0.38
LTA4H P09960 1/20 0.36
TSHR P16473 1/20 0.33
CTH P32929 1/20 0.33
CBS P35520 1/20 0.33
THPO P40225 1/20 0.33
CYP1A2 P05177 1/20 0.33
ADRB2 P07550 1/20 0.33
ADRB1 P08588 1/20 0.33
ADRB3 P13945 1/20 0.33
CA1 P00915 3/20 0.33
CA2 P00918 3/20 0.33
THRB P10828 1/20 0.32
P2RY2 P41231 1/20 0.31
EGLN1 Q9GZT9 1/20 0.31
ALOX15 P16050 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29223001 0.96 EPHX2 (0.37) EPHX2CYP2C19LTA4HTSHRCTH
SCHEMBL7214946 0.86 EPHX2 (0.39) EPHX2CYP2C19TSHRCTHCBS
SCHEMBL7268276 0.84 SMN1; SMN2 (0.38) EPHX2CYP2C19TSHRCTHCBS
SCHEMBL27386798 0.84 SMN1; SMN2 (0.38) EPHX2CYP2C19TSHRCTHCBS
SCHEMBL31123017 0.83 EPHX2 (0.34) EPHX2CYP2C19LTA4H
SCHEMBL7720634 0.82 LTA4H (0.36) LTA4HTSHRCA1CA2EGLN1
SCHEMBL25179494 0.81 CYP2D6 (0.33) EPHX2CYP2C19LTA4HEGLN1
SCHEMBL19772732 0.80 EPHX2 (0.41) EPHX2CYP2C19TSHRCTHCBS
SCHEMBL2562258 0.80 KDM4E (0.41) EPHX2LTA4HTSHRTHRBEGLN1
SCHEMBL2721141 0.80 TSHR (0.43) LTA4HTSHRCA1CA2EGLN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10723939-B2 Methods and compositions for treating a subterranean formation with a polymeric additive composite HALLIBURTON ENERGY SERVICES, INC. (US) 2020-07-28 US claimed
US-9255468-B2 Chelating agent-based self-diverting acidizing fluids and methods relating thereto HALLIBURTON ENERGY SERVICES, INC. (US) 2016-02-09 US claimed
US-6627772-B2 Preparation of N-[2-(carboxymethoxy) ethyl]-N-(carboxymethyl) glycine THE DOW CHEMICAL COMPANY 2003-09-30 US claimed
US-20020147360-A1 Intermediates for the preparation of N-[2-(carboxymethoxy) ethyl]-N-(carboxymethyl) glycine ATHEY PHILLIP S (US) 2002-10-10 US claimed
US-20020010367-A1 Intermediates for the preparation of N-[2-(carboxymethoxy) ethyl]-N-(carboxymethyl) glycine ATHEY PHILLIP S (US) 2002-01-24 US claimed
US-6288263-B1 AMINO CARBOXY ETHERS AND SALTS THE DOW CHEMICAL COMPANY 2001-09-11 US claimed
WO-2000076959-A2 INTERMEDIATES FOR THE PREPARATION OF (N)-[2-(CARBOXYMETHOXY) ETHYL]-(N)-(CARBOXYMETHYL) GLYCINE THE DOW CHEMICAL COMPANY (US) 2000-12-21 WO claimed
CN-113631039-A Photosensitizer and chelator combinations useful as insecticides 桑科能源股份有限公司 2021-11-09 CN disclosed
US-20200173034-A1 Corrosion Inhibition of HCL Treatment Fluids with Environmentally Compatible Solvent HALLIBURTON ENERGY SERVICES, INC. (US) 2020-06-04 US disclosed
US-6627772-B2 Preparation of N-[2-(carboxymethoxy) ethyl]-N-(carboxymethyl) glycine THE DOW CHEMICAL COMPANY 2003-09-30 US disclosed
US-20020147360-A1 Intermediates for the preparation of N-[2-(carboxymethoxy) ethyl]-N-(carboxymethyl) glycine ATHEY PHILLIP S (US) 2002-10-10 US disclosed
US-6392095-B2 HYDROLYSIS; HARD SURFACE CLEANING COMPOUNDS THE DOW CHEMICAL COMPANY 2002-05-21 US disclosed
US-20020010367-A1 Intermediates for the preparation of N-[2-(carboxymethoxy) ethyl]-N-(carboxymethyl) glycine ATHEY PHILLIP S (US) 2002-01-24 US disclosed
US-6288263-B1 AMINO CARBOXY ETHERS AND SALTS THE DOW CHEMICAL COMPANY 2001-09-11 US disclosed
WO-2000076959-A2 INTERMEDIATES FOR THE PREPARATION OF (N)-[2-(CARBOXYMETHOXY) ETHYL]-(N)-(CARBOXYMETHYL) GLYCINE THE DOW CHEMICAL COMPANY (US) 2000-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020010367-A1 Intermediates for the preparation of N-[2-(carboxymethoxy) ethyl]-N-(carboxymethyl) glycine GNMT, GRM1, CPN1 EPHX2 602/4885CYP2C19 1947/4885LTA4H 3335/4885
US-20020147360-A1 Intermediates for the preparation of N-[2-(carboxymethoxy) ethyl]-N-(carboxymethyl) glycine GNMT, GRM1, CPN1 EPHX2 602/4885CYP2C19 1947/4885LTA4H 3335/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.